Trials / Completed
CompletedNCT00245921
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,000 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-10-28
- Last updated
- 2013-02-08
Source: ClinicalTrials.gov record NCT00245921. Inclusion in this directory is not an endorsement.